Black Corpus Christi leaders talk about the importance of peer mentorship and helping others get ahead
NEWS continues our Black History Month celebration and coverage recognizing leaders in our community. As part of that ...
Daily Trojan3d
Candidates clash on AI, campus access at debate
Food access was another major topic of the debate. O’Beacain and Breitfelder aim to bring In-N-Out Burger to campus during finals and remove seed oils from the dining halls to promote healthier food ...
Renal & Urology News4d
Gamma Delta CAR T-Cell Therapy Fast Tracked for SLE With Extrarenal Involvement
The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma ...
IN8bio presented Phase 1 data on INB-100 at 2025 TCT
IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...
Campus Safety Magazine4d
University of Central Florida Fraternity Suspended Due to Hazing Involving Nazi Swastika
University of Central Florida Fraternity Banned Due to Hazing Involving Nazi Swastika, Phi Gamma Delta, UCF, antisemitism ...
Wyoming News1d
DKG used book sale set for first two weekends in March
CHEYENNE – Upsilon Chapter of Delta Kappa Gamma will hold its 41st book sale next month in the former Big Lots in Cheyenne Plaza, 3501 E. Lincolnway, next to Trampoline ...
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...
Investornewsbreaks TC Biopharm Holdings PLC (NASDAQ: TCBP) Completes Dosing In Phase 2B AML Trial, Reports Positive Early Data
TC BioPharm (NASDAQ: TCBP) announced the completion of patient dosing in Cohort A of its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for re ...
TC BioPharm: TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
Cohort B recruitment continues at multiple clinical sites across the United Kingdom EDINBURGH, Scotland, Feb. 10, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") ...